scholarly journals Pulmonary manifestations of Sjögren's syndrome

2016 ◽  
Vol 25 (140) ◽  
pp. 110-123 ◽  
Author(s):  
Thomas Flament ◽  
Adrien Bigot ◽  
Benjamin Chaigne ◽  
Helene Henique ◽  
Elisabeth Diot ◽  
...  

In 9–20% of cases, Sjögren's syndrome is associated with various respiratory symptoms. The most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial disease. The most common manifestation of ILD is nonspecific interstitial pneumonia in its fibrosing variant. Other types of ILD, such as organising pneumonia, usual interstitial pneumonia and lymphocytic interstitial pneumonitis, are rare. Their radiological presentation is less distinctive, and definitive diagnosis may require the use of transbronchial or surgical lung biopsy. Corticosteroid therapy is the mainstay of ILD treatment in Sjögren's syndrome, but the use of other immunosuppressive drugs needs to be determined. ILD is a significant cause of death in Sjögren's syndrome. Tracheobronchial disease is common in Sjögren's syndrome, characterised by diffuse lymphocytic infiltration of the airway. It is sometimes responsible for a crippling chronic cough. It can also present in the form of bronchial hyperresponsiveness, bronchiectasis, bronchiolitis or recurrent respiratory infections. The management of these manifestations may require treatment for dryness and/or inflammation of the airways. Airway disease has little effect on respiratory function and is rarely the cause of death in Sjögren's syndrome patients. Rare respiratory complications such as amyloidosis, lymphoma or pulmonary hypertension should not be disregarded in Sjögren's syndrome patients.

2011 ◽  
Vol 40 (1) ◽  
pp. e71-e86 ◽  
Author(s):  
Pierre-Yves Hatron ◽  
Isabelle Tillie-Leblond ◽  
David Launay ◽  
Eric Hachulla ◽  
Anne Laure Fauchais ◽  
...  

Lung ◽  
2007 ◽  
Vol 185 (3) ◽  
pp. 187-188 ◽  
Author(s):  
Hirokazu Tokuyasu ◽  
Etsuko Watanabe ◽  
Ryota Okazaki ◽  
Yuji Kawasaki ◽  
Ryutaro Kikuchi ◽  
...  

1998 ◽  
Vol 19 (4) ◽  
pp. 687-699 ◽  
Author(s):  
Hilary C. Cain ◽  
Paul W. Noble ◽  
Richard A. Matthay

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Hazlyna Baharuddin ◽  
Mohammad Hanafiah ◽  
Syazatul Syakirin Sirol Aflah ◽  
Mohd Arif Mohd Zim ◽  
Shereen Suyin Ch’Ng

Lymphocytic interstitial pneumonia (LIP) is a rare condition, commonly associated with Sjogren’s syndrome (SS). We report a 53-year-old woman with an incidental finding of an abnormal chest radiograph. LIP was diagnosed based on high-resolution computed tomography and lung biopsy, but treatment was not initiated. Six years later, she developed cough and dyspnoea, associated with dry eyes, dry mouth, and arthralgia. While being investigated for the respiratory symptoms, she developed cutaneous vasculitis and was treated with 1 mg/kg prednisolone, which resulted in the improvement of her respiratory symptoms. Physical examination revealed fine bibasal crepitations, active vasculitic skin lesions, and a positive Schirmer’s test. Investigations revealed a restrictive pattern in the pulmonary function test, stable LIP pattern in HRCT, and positive anti-Ro antibodies. She was treated with prednisolone and azathioprine for 18 months, and within this time, she was hospitalised for flare of LIP, as well as respiratory tract infection on three occasions. During the third flare, when she also developed cutaneous vasculitis, she agreed for prednisolone but refused other second-line agents. To date, she remained well with the maintenance of prednisolone 2.5 mg monotherapy for more than one year. The lessons from this case are (i) patients with LIP can be asymptomatic, (ii) LIP can precede symptoms of SS, and (iii) treatment decision for asymptomatic patients with abnormal imaging or patients with mild severity should be weighed between the risk of immunosuppression and risk of active disease.


2019 ◽  
Vol 40 (02) ◽  
pp. 235-254 ◽  
Author(s):  
Augustine Chung ◽  
May Lin Wilgus ◽  
Gregory Fishbein ◽  
Joseph P. Lynch

AbstractSjogren's syndrome (SS) is a chronic autoimmune disease characterized by mononuclear cells (principally lymphocytes) infiltrating exocrine glands (e.g., salivary and lacrimal glands), leading to destruction of exocrine epithelial cells and dryness of mucosal surfaces. Cardinal symptoms are dry eyes (xerophthalmia) and dry mouth (xerostomia). Extraglandular sites are affected in 30 to 40% of cases of SS (particularly neurological, kidneys, skin, and lungs). B cell hyperactivity, autoantibody production, and hypergammaglobulinemia are cardinal features of SS. Primary SS is not associated with other autoimmune diseases. However, SS can complicate diverse autoimmune disorders (particularly systemic lupus erythematosus, rheumatoid arthritis, and scleroderma); this form is termed “secondary SS.” Pulmonary involvement is usually not a dominant feature of SS, but may be severe in some cases. In this review, we discuss specific tracheal, bronchiolar, and pulmonary complications of SS including xerotrachea, bronchiolitis, bronchiectasis, interstitial lung disease, nonspecific interstitial pneumonia, usual interstitial pneumonia, lymphoid interstitial pneumonia, organizing pneumonia, acute fibrinous and organizing pneumonia, pulmonary cysts, pleural effusions, pulmonary amyloidosis, and bronchus- or lung-associated lymphomas.


Sign in / Sign up

Export Citation Format

Share Document